Induction of potent neutralizing antibody responses by a designed protein nanoparticle accine for respiratory syncytial virus
Marcandalli, JessicaInstitute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland -
Fiala, BrookeDepartment of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
Ols, SebastianDepartment of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden - Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
Perotti, MichelaInstitute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Institute of Microbiology, ETH Zürich, Switzerland
de van der Schueren, WillemClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA - Bluebird Bio, Seattle, USA
Snijder, JoostDepartment of Biochemistry, University of Washington, Seattle, USA
Hodge, EdgarDepartment of Medicinal Chemistry, University of Washington, Seattle, USA
Benhaim, MarkDepartment of Medicinal Chemistry, University of Washington, Seattle, USA
Ravichandran, RashmiDepartment of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
Carter, LaurenDepartment of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
Sheffler, WillDepartment of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
Brunner, LiviaVaccine Formulation Laboratory, University of Lausanne, Switzerland
Lawrenz, MariaVaccine Formulation Institute, Godalming, UK
Lanzavecchia, AntonioInstitute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
Sallusto, FedericaInstitute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Institute of Microbiology, ETH Zürich, Switzerland
Lee, Kelly K.Department of Medicinal Chemistry, University of Washington, Seattle, USA - Biological Physics Structure and Design Program, University of Washington, Seattle, USA
Veesler, DavidDepartment of Biochemistry, University of Washington, Seattle, USA
Correnti, Colin E.Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA
Stewart, Lance J.Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
Baker, DavidDepartment of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA - Howard Hughes Medical Institute, University of Washington, Seattle, USA
Loré, KarinDepartment of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden - Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
Perez, LaurentInstitute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - European Virus Bioinformatics Center, Jena, Germany
King, Neil P.Department of Biochemistry, University of Washington, Seattle, USA - Institute for Protein Design, University of Washington, Seattle, USA
English
Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its identification as the main target of neutralizing antibodies have provided new opportunities for development of an effective vaccine. Here, we describe the structure-based design of a self-assembling protein nanoparticle presenting a prefusion-stabilized variant of the F glycoprotein trimer (DS-Cav1) in a repetitive array on the nanoparticle exterior. The two-component nature of the nanoparticle scaffold enabled the production of highly ordered, monodisperse immunogens that display DS-Cav1 at controllable density. In mice and nonhuman primates, the full-valency nanoparticle immunogen displaying 20 DS-Cav1 trimers induced neutralizing antibody responses ∼10-fold higher than trimeric DS-Cav1. These results motivate continued development of this promising nanoparticle RSV vaccine candidate and establish computationally designed two-component nanoparticles as a robust and customizable platform for structure-based vaccine design.